Dundas Partners’s ResMed RMD Stock Holding History

Dundas Partners’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$45.6M	Sell	203,021 -1,941	-0.9%	-$484K	3.63%	11
2025 Q4	$49.4M	Buy	204,962 +29,845	+17%	+$7.63M	3.48%	14
2025 Q3	$47.9M	Buy	175,117 +22,933	+15%	+$6.26M	3.38%	12
2025 Q2	$39.3M	Hold	152,184	–	–	2.73%	16
2025 Q1	$34.1M	Buy	152,184 +11,622	+8%	+$2.71M	2.51%	20
2024 Q4	$32.1M	Hold	140,562	–	–	2.25%	26
2024 Q3	$34.3M	Buy	140,562 +7,875	+6%	+$1.76M	2.47%	22
2024 Q2	$25.4M	Buy	132,687 +23,819	+22%	+$4.83M	1.97%	27
2024 Q1	$21.6M	Buy	+108,868	New	+$19.9M	1.7%	31

Other funds holding RMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dundas Partners's RMD Position: Q1 2026 in Review

Dundas Partners reduced its ResMed (RMD) stake by 0.95% in Q1 2026, selling an estimated $484K and leaving 203,021 shares worth $45.6M. The position accounts for 3.63% of the portfolio, ranked #11.

Dundas Partners first reported a position in RMD in Q1 2024 and has held it in 9 quarters since. The position peaked at $49.4M in Q4 2025. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

Dundas Partners held 203,021 shares of ResMed worth $45.6M as of Q1 2026.
Dundas Partners sold 1,941 ResMed shares in Q1 2026, an estimated $484K.
ResMed made up 3.63% of Dundas Partners's portfolio in Q1 2026, its #11 holding.
Dundas Partners first reported a position in ResMed in Q1 2024 and has held it in 9 quarters since.
Dundas Partners's ResMed position peaked at $49.4M in Q4 2025.
938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Dundas Partners's 13F filing for Q1 2026, filed 14 May 2026.